4//SEC Filing
Ballal Rahul D. 4
Accession 0001415889-24-024990
CIK 0001672619other
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 8:36 PM ET
Size
13.0 KB
Accession
0001415889-24-024990
Insider Transaction Report
Form 4
Ballal Rahul D.
Director
Transactions
- Sale
Common Stock
2024-10-08$28.17/sh−10,420$293,557→ 22,341 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-08−4,106→ 12,322 totalExercise: $5.52Exp: 2032-01-28→ Common Stock (4,106 underlying) - Exercise/Conversion
Common Stock
2024-10-08$5.52/sh+4,106$22,665→ 32,761 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-08−6,314→ 69,428 totalExercise: $19.68Exp: 2029-05-16→ Common Stock (6,314 underlying) - Exercise/Conversion
Common Stock
2024-10-08$19.68/sh+6,314$124,260→ 28,655 total
Footnotes (4)
- [F1]The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $28.00 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- [F4]The option, originally for 32,849 shares, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter.
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001805097
Filing Metadata
- Form type
- 4
- Filed
- Oct 9, 8:00 PM ET
- Accepted
- Oct 10, 8:36 PM ET
- Size
- 13.0 KB